| Drug Name |
Enzalutamide |
| Drug ID |
BADD_D00775 |
| Description |
Enzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012. |
| Indications and Usage |
Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. |
| Marketing Status |
approved |
| ATC Code |
L02BB04 |
| DrugBank ID |
DB08899
|
| KEGG ID |
D10218
|
| MeSH ID |
C540278
|
| PubChem ID |
15951529
|
| TTD Drug ID |
D0QK5X
|
| NDC Product Code |
16812-010; 11014-0003; 42385-733; 65392-2209; 0469-0725; 59285-018; 65015-876; 15308-1121; 0469-1725; 65129-1376; 0469-0625; 54893-0044; 55111-976; 0469-1125; 62128-0388; 68554-0106; 77382-0150; 0469-0125; 70277-001; 76302-019 |
| UNII |
93T0T9GKNU
|
| Synonyms |
enzalutamide | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide | enzalutamide D3 | HC-1119 | HC 1119 | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide | Xtandi | MDV 3100 | MDV3100 | MDV-3100 |
